Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | OAT | P04181 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670790 | 0.92 | BRD4 (0.50) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1650294 | 0.92 | BRD4 (0.50) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL872959 | 0.83 | — | — | |
| SCHEMBL2083101 | 0.83 | ABAT (0.48) | ABATMAPTKMT2AOATCYP1A2 | |
| SCHEMBL2079668 | 0.83 | ABAT (0.48) | ABATMAPTKMT2AOATCYP1A2 | |
| SCHEMBL6370539 | 0.81 | BRD4 (0.44) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7472913 | 0.79 | CHRNB2 (0.54) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL1297377 | 0.79 | CHRNB2 (0.54) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7472907 | 0.79 | CHRNB2 (0.54) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17710064 | 0.79 | CHRNB2 (0.54) | BRD4CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359297-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2016-06-07 | — | — | US | disclosed |
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2014-07-10 | — | — | US | disclosed |
| EP-2493304-B1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | LUNDBECK & CO AS H (DK) | 2014-02-26 | — | — | EP | disclosed |
| US-8633190-B2 | Spirolactam derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-01-21 | — | — | US | disclosed |
| EP-2493304-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011053575-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140194424-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | BRD4 3155/4885CHRNB2 3760/4885CHRNA4 3012/4885 |
| US-20110098299-A1 | SPIROLACTAM DERIVATIVES AND USES OF SAME | REN, AGTR1, PDE6D | BRD4 3155/4885CHRNB2 3760/4885CHRNA4 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.